Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The mortality/dementia-related psychosis claim is directly supported by the provided ABILIFY label excerpt. However, two suicidality/monitoring claims rely on label text that is explicitly framed for patients treated with antidepressants, and the provided excerpt does not establish that this antidepressant-specific monitoring language applies to ABILIFY as such; therefore those claims are treated as unsupported/not confirmed for ABILIFY labeling.
Category Scores
Accurate Statements
Elderly patients with dementia-related psychosis treated with antipsychotic drugs have increased risk of death; ABILIFY is not approved for the treatment of dementia-related psychosis.
5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis: “Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY (aripiprazole) is not approved for the treatment of patients with dementia-related psychosis [see BOXED WARNING].”
Unsupported Statements
Suicidal thoughts/behaviors with antidepressants require monitoring (including for clinical worsening and unusual changes in behavior), with caregiver alerting (as an ABILIFY labeling requirement).
The provided label excerpt for this topic is explicitly about “patients being treated with antidepressants” (W&P 5.3) and does not, in the excerpt shown, establish that the same monitoring/caregiver-alert language is an ABILIFY-specific precaution for ABILIFY use. Therefore this cannot be confirmed as fully supported for ABILIFY based on the supplied text.
Close monitoring language for depression worsening and suicide risk during antidepressant treatment and dose adjustments applies as ABILIFY labeling counseling/monitoring.
The patient counseling excerpt is framed around patients taking antidepressants (“Patients… encouraged to be alert… especially early during antidepressant treatment and when the dose is adjusted up or down…”). The provided excerpt does not link this counseling language to ABILIFY specifically.
Contradictions
Important Omissions
The provided label excerpt also contains additional boxed/warning-related monitoring considerations in elderly dementia-related psychosis (e.g., assess for difficulty swallowing or excessive somnolence) that were not addressed in the evaluated warning claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Mortality/dementia-related psychosis risk was correctly represented. However, treating antidepressant-specific suicidality monitoring/counseling as generally applicable to ABILIFY based on the excerpt introduces the risk of mischaracterizing the labeling scope for ABILIFY; this could lead to inaccurate counseling/monitoring expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Suicidality monitoring/caregiver-alert and depression-worsening counseling were taken from label sections explicitly referring to patients treated with antidepressants, without evidence in the supplied excerpt that this language is an ABILIFY-specific warning/precaution for ABILIFY indications.
Suggested Improvement
Limit the suicidality/close-monitoring/caregiver-alert claims to the antidepressant-specific context as written in W&P 5.3 and the patient counseling excerpt, or provide ABILIFY-specific labeling text that explicitly applies these warnings to ABILIFY for the relevant indication/population.